Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.

Abstract

ABSTRACT:

We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.

• Authors: Natalie Hasenauer, Takahiro Higuchi, Barbara Deschler-Baier, Philipp E Hartrampf, Martin G Pomper, Steven P Rowe, Martin Fassnacht, Andreas K Buck, Rudolf A Werner
• Journal: Clinical nuclear medicine (Clin Nucl Med) Vol. 47 Issue 7 Pg. 651-652 (Jul 01 2022) ISSN: 1536-0229 [Electronic] United States
• PMID: 35085172 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Gallium Radioisotopes
• Oligopeptides
• Radiopharmaceuticals
• Edetic Acid

Topics

• Carcinoma, Neuroendocrine
• Edetic Acid
• Gallium Radioisotopes
• Humans
• Male
• Middle Aged
• Oligopeptides
• Positron Emission Tomography Computed Tomography
• Precision Medicine
• Prostatic Neoplasms (pathology)
• Radiopharmaceuticals
• Thyroid Neoplasms (diagnostic imaging, radiotherapy)